Upregulation of kinesin family member 4A enhanced cell proliferation via activation of Akt signaling and predicted a poor prognosis in hepatocellular carcinoma

Yanlin Huang1, Hongbo Wang2, Yifan Lian2, Xiaojuan Wu1, Liang Zhou1, Jialiang Wang2, Meihai Deng3 and Yuehua Huang1,2

Abstract
Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death worldwide, and the molecular pathogenesis and development of HCC are largely unknown. In the present study, we found that KIF4A expression was upregulated in HCC (678 samples, \( P = 2.03 \times 10^{-8} \)) based on a meta-analysis of Oncomine database. We further confirmed that both KIF4A mRNA and protein expressions were overexpressed in human HCC tumour tissues as well as cancer cell lines. Higher KIF4A expression was correlated with poorer overall survival (\( P < 0.0001 \)) and disease-free survival (\( P < 0.0337 \)) in HCC patients. We constructed in vitro KIF4A overexpression and depletion HCC cell models. KIF4A overexpression significantly enhanced cellular proliferation and clonogenic abilities, whereas KIF4A depletion caused a dramatic increase of cells with abnormal chromosome segregation and subsequently resulted in augmentation of apoptosis in HCC cells. In addition, we demonstrated that KIF4A depletion was related to inhibition of Akt kinase activity and induction of intrinsic apoptosis signaling pathway. Taken together, KIF4A may act as a prognostic biomarker and potential therapeutic target in human HCC.

Introduction
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and the third most frequent cause of cancer-related death worldwide1. The risk factors for HCC oncogenesis include chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, aflatoxin exposure, alcohol or drugs abuse, and metabolic disorders in liver. Despite great advances having been made to increase significantly the detection rate in early stages of HCC patients, the 5-year overall survival rate of patients with liver cancer, particularly in intermediate stage and advanced stage, is still extremely low2. On the other hand, although a growing body of related research was performed in order to explain the oncogenesis process of HCC, the molecular basis still remains obscure. Therefore, revealing the complicated molecular mechanism of pathogenesis and development of liver cancer is currently an urgent global health issue.

Over the past decade, there has been an improvement in the classification of the molecular pathogenesis of HCC3. Main drivers responsible for tumour initiation and progression have been discovered through genomic analyses. Common mutations affect telomere maintenance (telomere reverse transcriptase (TERT)), WNT pathway

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Official journal of the Cell Death Differentiation Association
activation (β-catenin (CTNNB1)), inactivation of cellular tumour antigen p53 (TP53), etc. Certain genetic and epigenetic events lead to activation of specific signalling pathways, including regulation of cell cycle progression. Large amounts of published studies show that suppressing cell cycle arrest and/or promoting cell cycle transition could boost the proliferation of pre-cancerous cells or cancer cells and are related to HCC tumorigenesis and progression. The spindle assembly checkpoint (SAC) is a quality control mechanism that ensures accurate chromosome segregation during mitosis, and is thus important for cell cycle regulation. The SAC delays cell cycle progression until all chromosomes have successfully made spindle–microtubule attachments. Defects in the SAC generate aneuploidy and may facilitate tumorigenesis.

Kinesin superfamily proteins (KIFs) share a conserved motor domain, and there are a class of microtubule-dependent molecular motor proteins that have been shown to participate in multiple cellular activities, including mitosis, organelles and vesicles transportation. In mitosis, the active movement of kinesins guarantees the precise orchestration of mitotic events and normal activity of SAC. Today, 45 human and murine kinesin proteins have been found and classified into 14 families. KIF4A, an N-type kinesin belonging to the kinesin-4 family, contains the ATPase/motor domain that binds to microtubules to provide mechanochemical force and plays a pivotal role in chromosome segregation and mitotic spindle organization during mitosis. KIF4A has been found overexpressed in several malignancies, including oral and pulmonary carcinomas, cervical cancer, and breast cancer, and its overexpression is associated with poor prognosis in these cancers.

In the present study, we showed that KIF4A is overexpressed in HCC tissues and cell lines, and high level of KIF4A predicts a poor prognosis in HCC patients. Using KIF4A depletion and overexpression HCC cell models, we demonstrated that KIF4A promotes cell proliferation and clonogenic potential, mainly through maintenance of mitotic progression and protection from apoptosis. We proposed that KIF4A could be a diagnostic biomarker and promising molecular target for anticancer therapy in HCC.

Results

KIF4A expression increases in HCC tissues and cell lines

To assess the role of KIF4A in HCC, we analysed four microarray datasets from Oncomine database, and found significant overexpression of KIF4A in the majority of HCC tissues compared with adjacent non-neoplastic controls (Supplementary Fig. S1). The median rank of KIF4A in upregulated genes of HCC was 262.0, based on a meta-analysis across four datasets using the Oncomine algorithms (678 samples, \(P = 2.03 \times 10^{-8}\), Fig. 1a). To further validate the relationship between KIF4A expression status and HCC, we detected the mRNA level of tumour tissues compared with paired non-cancerous tissues using qPCR. Data confirmed that KIF4A mRNA levels were significantly elevated in tumour tissues (72/78, 92.3%, Fig. 1b). We also detected the KIF4A protein levels in 18 paired primary HCC tissues and the corresponding adjacent normal tissues using western blotting. Results showed that KIF4A protein levels (18/18,100%) were increased in primary liver cancer tissues compared with adjacent normal liver tissues (Fig. 1c, d). To further explore the potential role of KIF4A in HCC tumorigenesis, we detected the protein expression of KIF4A in 2 normal liver and 11 different HCC cell lines using western blotting. Compared with the normal liver cell lines THLE-2 and LO2, KIF4A was overexpressed in all the detected HCC cell lines (Fig. 1e, f). Taken together, these data indicated that KIF4A expression was increased in HCC tumour tissues and cells.

Upregulation of KIF4A is associated with poor prognosis in liver cancer

To further investigate the KIF4A expression in fresh HCC tissues, we employed IHC staining with a total of 136 HCC samples from Sun Yat-sen University Cancer Center after liver section and followed up for 100 months. Among the patients, there were 18 women (13.2%) and 118 men (86.83%) with an age range from 20 to 78 years. Most patients (81.6%) had a single tumour, and in the majority the tumour size was >3 cm (118/136 cases, 86.7%). In the case of histological classification, 97 cases (71.3%) were classified as TNM stage I, 6 cases (4.4%) as TNM stage II, 22 cases (16.2%) as TNM stage III, and 11 cases (8.1%) as TNM stage IV. We identified that KIF4A expression was specifically detected in the nucleus of HCC cell from the cancer tissues in the vast majority of HCC samples (122/136 cases, 89.7%), while others presented negative expression (14/136 cases, 10.3%). No signals were found in all the corresponding adjacent normal tissues (Supplementary Figure S2). According to the IHC results, 68 cases were defined as low KIF4A expression, while the other 68 cases were identified as high expression (Fig. 2a). Further investigation of the relationship between KIF4A protein expression and the clinicopathological features is summarized in Table 1. Results indicated that KIF4A protein expression levels were markedly correlated with encapsulation (\(P = 0.036\)), tumour size (\(P = 0.004\)), and survival (\(P = 0.0003\)). According to Kaplan–Meier survival analysis, patients with higher KIF4A expression predicted a decreased OS (overall survival, \(P < 0.0001\)) and DFS (disease-free survival, \(P < 0.0001\), Fig. 2b). When we stratified the data based on the TNM stage, higher KIF4A levels were found, suggesting a poorer OS (\(P = 0.0009\)) and DFS (\(P = 0.0003\)).
Fig. 1 KIF4A expression increases in HCC tissues and cell lines. a KIF4A mRNA expression in liver cancer tissues is higher than that in normal tissues from Oncomine database. Dataset 1, Wurmbach Liver; Dataset 2, Roessler Liver 1; Dataset 3, Roessler Liver 2; Dataset 4, Mas Liver. Cell colour and the number above the cell in the lower panel indicate the best gene rank percentile for the analysis. Red, upregulated; blue, downregulated. b The mRNA levels of KIF4A from 78 patients were tested by quantitative PCR using paired t-test. c The protein levels of KIF4A in HCC tissues and matched non-cancerous tissues from 18 patients with HCC were determined by western blotting assay. N non-cancerous, C cancer. Fold change of KIF4A protein with respect to non-cancerous specimens was normalized to GAPDH. The quantification of western blotting is shown in (d). e KIF4A protein expressions in nine HCC cell lines (QGY-7703, BEL-7404, Hepa3B, MHCC-97L, Huh7, PLC/PRF/5, BEL-7405, SMMC-7721, SK-HEP-1), two hepatoblastoma cell lines (HepG2, HepG2.215), and two immortalized liver cell lines (THLE-2 and LO2) were examined by western blotting. f Quantification of KIF4A expressions in different cell lines is shown.
Fig. 2 Upregulation of KIF4A is associated with poor prognosis in liver cancer. 

a) Immunohistochemical staining of KIF4A protein expression in 136 HCCs and their corresponding non-cancerous tissues. Two representative cases were shown. The scale bar of the left panel is 500 μm. The scale bar of the middle and right panels is 50 μm.

b) KIF4A expression was associated with OS (n = 136, \(P < 0.001\)) and DFS (n = 136, \(P < 0.001\)) according to Kaplan–Meier analysis.

c) Subgroup analysis for OS (\(P = 0.009\)) and DFS (\(P = 0.005\)) of HCC patients in TNM stage I.

d) Subgroup analysis for OS (\(P = 0.0192\)) and DFS (\(P = 0.0149\)) of HCC patients in TNM stage II + III + IV.

Huang et al. Cell Death and Disease (2018) 9:141
Consistent results showed that in the TNM stage II + III + IV group, higher KIF4A expression also was accompanied by poorer OS ($P = 0.0192$) and DFS ($P = 0.0149$, Fig. 2d). Multivariate Cox regression analysis showed that KIF4A expression ($HR = 1.147$, $P = 0.001$), age ($HR = 2.265$, $P = 0.0336$), AFP ($HR = 1$, $P = 0.004$), AST ($HR = 1.025$, $P < 0.001$), bilirubin

| Parameters          | Total | KIF4A expression | $P$ value |
|---------------------|-------|------------------|-----------|
|                     |       | Low | High |
| Gender              |       |     |     |
| Female              | 18    | 6   | 12  | 0.205 |
| Male                | 118   | 62  | 56  |       |
| Age (years)         |       |     |     |
| $\leq 50$           | 85    | 43  | 42  | 1     |
| $>50$               | 51    | 25  | 26  |       |
| Encapsulation       |       |     |     |
| Yes                 | 74    | 31  | 43  | 0.036*|
| No                  | 59    | 36  | 23  |       |
| Tumour size (cm)    |       |     |     |
| $\leq 3$            | 18    | 15  | 3   | 0.004*|
| $>3$                | 115   | 52  | 63  |       |
| Tumour number       |       |     |     |
| Single              | 87    | 58  | 49  | 0.122 |
| Multiple            | 25    | 9   | 16  |       |
| Metastasis          |       |     |     |
| Yes                 | 121   | 62  | 59  | 0.561 |
| No                  | 12    | 5   | 7   |       |
| Cirrhosis           |       |     |     |
| Negative            | 29    | 18  | 11  | 0.398 |
| Positive            | 104   | 49  | 55  |       |
| Thrombosis          |       |     |     |
| Yes                 | 13    | 6   | 7   | 1     |
| No                  | 123   | 62  | 61  |       |
| Differentiation grade|     |     |     |
| Well                | 6     | 2   | 4   | 0.288 |
| Middle              | 120   | 59  | 61  |       |
| Poor                | 5     | 4   | 1   |       |
| Ascites             |       |     |     |
| Yes                 | 12    | 6   | 6   | 1     |
| No                  | 124   | 62  | 62  |       |
| HbsAg               |       |     |     |
| Negative            | 17    | 11  | 6   | 0.34  |
| Positive            | 115   | 56  | 59  |       |
| HbeAg               |       |     |     |
| Negative            | 124   | 63  | 61  | 1     |
| Positive            | 8     | 4   | 4   |       |

Statistical analysis was performed by the Pearson $\chi^2$-test.

| Parameters      | Total | KIF4A expression | $P$ value |
|-----------------|-------|------------------|-----------|
| $\text{AFP (ng/ml)}$ |       |  |     |
| $\leq 400$      | 70    | 39  | 31  | 0.295 |
| $>400$          | 62    | 28  | 34  |       |
| $\text{PT (s)}$ |       |  |     |
| $\leq 14$       | 101   | 50  | 51  | 0.683 |
| $>14$           | 31    | 17  | 14  |       |
| $\text{PLT (10^9/L)}$ |       |  |     |
| $\leq 100$      | 9     | 5   | 4   | 1     |
| $>100$          | 123   | 62  | 61  |       |
| $\text{ALT (U)}$ |       |  |     |
| $\leq 40$       | 68    | 36  | 32  | 0.604 |
| $>40$           | 65    | 31  | 34  |       |
| $\text{AST (U)}$ |       |  |     |
| $\leq 100$      | 59    | 37  | 22  | 0.015*|
| $>100$          | 74    | 30  | 44  |       |
| $\text{Albumin (g/L)}$ |       |  |     |
| $\leq 17.1$     | 72    | 40  | 32  | 0.225 |
| $>17.1$         | 61    | 27  | 34  |       |
| $\text{TNM stage}$ |     |  |     |
| I                | 97    | 52  | 45  | 0.225 |
| II+III+IV       | 39    | 16  | 23  |       |
| $\text{Recurrence}$ |     |  |     |
| Yes              | 78    | 40  | 38  | 0.86  |
| No               | 53    | 26  | 27  |       |
| $\text{Survival}$ |     |  |     |
| Died             | 62    | 20  | 42  | 0.0003*|
| Alive            | 74    | 48  | 26  |       |

*Represent $P$ values with significant difference
increased in siKIF4A transfectants, indicating that KIF4A is required for proper mitosis maintenance.

KIF4A promotes proliferation and clonogenicity of HCC cells

To address the potential role of KIF4A in HCC progression, KIF4A knockdown and overexpression of HCC cell models were constructed in SMMC-7721 and BEL-7404 cells with two distinct siRNA duplexes and the lentivirus infection method, respectively. As shown in Fig. 3, KIF4A expression was almost eliminated in knockdown cell models (Fig. 3a) and increased in overexpressing cell models, indicating successful establishment (Fig. 3b). MTT assay was then performed to assess cell viability at the indicated times. Data showed that the inhibition of KIF4A markedly declined the HCC cells' viability (Fig. 3c). On the contrary, cellular proliferation ability greatly increased after KIF4A overexpression (Fig. 3d). Colony formation assay showed that, compared with the siNC cells, both the size and number of siKIF4A transfectants were dramatically decreased (Fig. 3e). On the other hand, the size and number were significantly increased in KIF4A-overexpressing cells (Fig. 3f). We also investigated the proliferation-related marker Ki67 in 53 fresh HCC tissues by immunohistochemistry (IHC) (Supplementary Fig. S3a). The results suggested that there was a significant positive correlation between expressions of KIF4A and Ki67 (Supplementary Figure S3b). Taken together, these results indicated that KIF4A played an important role in HCC proliferation and clonogenicity.

KIF4A is required for proper mitosis maintenance

To disclose the underlying mechanism responsible for KIF4A-mediated HCC cell proliferation and clonogenicity, the effect of KIF4A knockdown was further evaluated in SMMC-7721 cells. We first observed that through immunofluorescence staining the number of multinucleated cells increased after siKIF4A treatment, suggesting that KIF4A knockdown might affect chromosome misalignment and mitosis (Fig. 4a, b). We further investigated whether KIF4A depletion could cause cell cycle arrest. SMMC-7721 and BEL-7404 were synchronized at G1/S transition by double thymidine block and then released to fresh media to continue the cell cycle process. We harvested the cells and analysed their cell cycle distribution at the indicated time points. Results showed that the fraction of cells in G2/M phase was significantly increased in siKIF4A transfectants, indicating that KIF4A knockdown can trigger the G2/M phase arrest in both SMMC-7721 and BEL-7404 cells (Fig. 4c, d). According to the previous study on oral cancer, KIF4A depletion contributes to activating the SAC during cell division. SAC monitors the attachment of chromosome to the mitotic spindle and allows the chromosome separates precisely, and it is an inhibitor of the anaphase-promoting complex or cyclosome (APC/C) and CDC20. The APC/C, a major ubiquitin ligase activated by CDC20, regulates the exact timing of cyclin B degradation to trigger anaphase onset. When chromosomal misalignment occurs, degradation of cyclin B1 is inhibited. Consistent with the above research, we measured the expression levels of CDC20 and cyclin B1 in KIF4A knockdown cells and found that the expression of CDC20 was significantly downregulated, while cyclin B1 was upregulated (Fig. 4e, f). In summary, these data suggested that KIF4A might be essential for proper mitotic progression by precisely orchestrating chromosome alignment and segregation.

KIF4A maintains cell survival via activation of PI3K/Akt pathway

Incomplete and aberrant mitosis often leads to cell apoptosis. Since we observed that KIF4A depletion caused abnormal mitotic progression, we measured the relationship of KIF4A regulation and cell apoptosis through Annexin V-FITC/PI dual staining assay. Flow cytometry analysis showed that KIF4A depletion increased the percentage of apoptotic cells (Fig. 5a, b), while apoptotic rates decreased significantly in KIF4A-overexpressing cell lines (Fig. 5c, d). According to a currently published study, KIF4A knockdown decreased the expression of p-Akt. We speculated that KIF4A may contribute to maintaining the cell survival by regulating the PI3K/Akt pathway in our models. Western blotting results showed that protein levels of p-Akt (Ser473) and p-Akt (Thr308) were downregulated, while the total amount of Akt remained unchanged. Expression of Bax, an important pro-apoptosis factor downstream of Akt, was dramatically upregulated and anti-apoptosis factor Bcl-2 was downregulated. Most importantly, we found that cellular apoptosis markers such as cleaved-caspase-3, cleaved-caspase-7, and cleaved-PARP were significantly upregulated after KIF4A depletion (Fig. 5e). Similarly, we assessed the expression of the above proteins in KIF4A-overexpressing cell lines, which had been cultured without serum for 48 h. Compared with control cells, total Akt expression was unchanged, p-Akt (Ser473) and p-Akt (Thr308) were dramatically upregulated, Bcl-2 was downregulated, and Bax was downregulated. Apoptosis markers including cleaved-caspase-3, cleaved-caspase-7, and cleaved-PARP were downregulated significantly in KIF4A-overexpressing cell lines (Fig. 5f). These results
| Variables            | Univariate analysis | Multivariate analysis |
|----------------------|---------------------|-----------------------|
|                      | Hazard ratio | 95% CI   | P value | Hazard ratio | 95% CI   | P value |
| Gender               | 1.242       | 0.796–2.006 | 0.375   |            |           |         |
| Age (years)          | 1.003       | 0.988–1.019 | 0.689   | 2.265       | 1.064–6.188 | 0.036* |
| Encapsulation        | 1.714       | 1.266–2.319 | <0.001* |            |           |         |
| Tumour size (cm)     | 1.149       | 1.097–1.203 | <0.001* |            |           |         |
| Tumour number        | 2.683       | 1.809–3.979 | <0.001* |            |           |         |
| Metastasis           | 3.143       | 1.587–6.225 | <0.001* |            |           |         |
| Cirrhosis            | 1.881       | 1.139–3.107 | 0.014*  | 2.253       | 0.981–5.174 | 0.056 |
| Thrombosis           | 4.425       | 2.687–7.286 | <0.001* |            |           |         |
| Differentiation grade| 0.904       | 0.414–1.973 | 0.8     |            |           |         |
| Ascites              | 1.746       | 1.032–2.955 | 0.038*  |            |           |         |
| HBsAg                | 0.961       | 0.550–1.681 | 0.889   |            |           |         |
| HBeAg                | 1.685       | 0.674–4.125 | 0.265   |            |           |         |
| AFP (ng/ml)          | 1           | 1.000–1.000 | <0.001* | 1           | 1.000–1.000 | 0.004* |
| PT (s)               | 0.977       | 0.941–1.014 | 0.214   |            |           |         |
| PLT (10^9/L)         | 1.002       | 1.000–1.005 | 0.107   |            |           |         |
| ALT (U)              | 1.009       | 1.000–1.017 | 0.042*  |            |           |         |
| AST (U)              | 1.029       | 1.021–1.037 | <0.001* | 1.025       | 1.011–1.038 | <0.001* |
| Albumin (g/L)        | 0.946       | 0.909–0.984 | 0.005*  |            |           |         |
| Bilirubin (μmol/L)   | 1.035       | 1.008–1.063 | 0.013*  | 1.069       | 1.019–1.121 | 0.006* |
| TNM stage            | 1.698       | 1.469–1.964 | <0.001* | 2.043       | 1.568–2.637 | <0.001* |
| Recurrence           | 2.111       | 1.264–3.542 | 0.004*  |            |           |         |
| KIF4A scores         | 1.159       | 1.105–1.241 | <0.001* | 1.147       | 1.061–1.240 | 0.001* |

Statistical analysis was performed by Cox test analysis

HCC hepatocellular carcinoma, HBsAg hepatitis B surface antigen, HBeAg hepatitis B e antigen, PT prothrombin time, PLT platelet, ALT alanine transaminase, AST aspartate transaminase

*Represent P values with significant difference
indicated that KIF4A maintained cell survival by activating the Akt signaling pathway.

Skp2 correlates positively with KIF4A expression in HCC

Skp2 is a component of the SCF<sub>Skp2</sub> ubiquitin E3 ligase complex, and responsible for recruiting substrate proteins and subsequent ubiquitin-proteasome-dependent degradation<sup>20</sup>. Overexpression of Skp2 is well known for its strong association with aggressive tumour behaviour and poor clinical outcome in a variety of cancers, including HCC<sup>21</sup>. Recently, Xu et al.<sup>22</sup> reported that KIF14, a structurally and functionally similar protein to KIF4A, and...
Fig. 4 (See legend on next page.)
also a member of the kinesin superfamily of proteins, regulated the expression of Skp2 in HCC through an undefined mechanism. Due to its significant role in cancer development and progression, we wondered whether Skp2 expression was also related to KIF4A in this study. We silenced Skp2 with siRNAs in SMMC-7721 and BEL-7404 cells. Effective knockdown of Skp2 led to significantly downregulation of CDC20 and upregulation of cyclin B1 compared with control cells (Fig. 6a). Furthermore, we performed immunohistochemical staining of Skp2 and KIF4A in 53 HCC samples, graded, and performed correlation analysis. We found that Skp2 showed a significant positive correlation with KIF4A in HCC tissues (Fig. 6b, c). These results suggested that expression levels of Skp2 and KIF4A correlated positively with each other in HCC.

Discussion

HCC is characterized by multiple cancer hallmarks, including genetic and epigenetic alterations that cause uncontrolled cellular proliferation and cell cycle regulation. In recent years, there has been a surging interest in studying the novel genes that are involved in cancer development and progression. Here, we demonstrated that KIF4A is overexpressed in HCC tissues and cell lines, and KIF4A overexpression predicts a poor prognosis for HCC patients. We then used in vitro HCC cell models to address the molecular mechanism by which KIF4A promotes hepatic malignant transformation and tumour progression. Through loss-of-function study we found that KIF4A depletion induces G2/M phase arrest and suppresses mitotic progression. Moreover, we showed that KIF4A depletion induces apoptosis by inhibiting Akt kinase activity in HCC cells. In addition, Skp2 knockdown decreases KIF4A expression and their expression levels show a positive correlation in HCC tissues. Thus, this study presents a key role of KIF4A in promoting cellular growth and maintaining normal mitotic progression in HCC.

Similar to other investigations of rapid growth rate in HCC, KIF4A overexpression enhances proliferation and colony formation abilities in HCC cells, highlighting its importance in HCC progression. KIF4A participates in chromosome condensation and segregation in multiple steps during the process of mitotic division by acting as an essential component in regulating the completion of cytokinesis and anaphase spindle dynamics. As a matter of fact, KIF4A depletion may cause defects in mitotic chromosome formation and subsequent mitotic checkpoint activation, resulting in uncompleted cytokinesis. In line with this expectation, a published study in oral cancer cells demonstrated that KIF4A knockdown may lead to SAC activation, which finally causes the G2/M arrest. Consistent with these studies, we also observed that, after KIF4A depletion, a large amount of HCC cells were arrested in G2/M phase and became multinucleated. Considering its conserved role in cytokinesis, it is likely that KIF4A supported HCC cell growth by a similar mechanism that maintains proper chromosome architecture during mitosis. Therefore, we can speculate that KIF4A overexpression possibly contributes to uncontrolled cell cycle progression and division in hepatocytes, which may cause HCC initiation and development.

Apoptosis is a genetically regulated, cellular suicide mechanism that plays a crucial role in maintenance of physiological homeostasis and development. There are two typical apoptosis signalling pathways, namely extrinsic and intrinsic pathways, which converge on the effector molecules caspase-3 and -7 to cleave the downstream targets and induce apoptotic phenotype. Our data showed that KIF4A knockdown resulted in decline of Bcl-2 expression, increase of Bax expression and cleavage of caspase-9, which are mediators of the intrinsic apoptosis pathway. Disassociation of Bcl-2 with Bax and suppressing its translocation to the mitochondria pathway. Moreover, activation of Akt is sufficient to block the release of cytochrome c by directly phosphorylating Bax and suppressing its translocation to the mitochondria membrane, and a recent study reported that silencing KIF4A inhibited the activation of Akt. Therefore, we tried to define whether KIF4A would regulate Bax expression through the Akt signalling pathway. In compliance with the above research, our study showed that KIF4A knockdown suppressed the phosphorylation of Akt, along with a higher expression of Bax protein. Contradicting results were obtained using the KIF4A-
**Fig. 5** (See legend on next page.)
overexpressing cell models. Therefore, these results suggest that KIF4A may be involved in the intrinsic pathway and may protect cells from apoptosis by activating the PI3K/Akt pathway. However, the exact mechanism needs further characterization.

Worldwide, China has been recognized as an area with a significantly high incidence of HBV infection. Evidence shows that HBV-related cancer development and poor prognosis are independently associated with several viral factors, such as HBV DNA, HBV genotype C, and HBV core promoter mutations. The risk of HCC development in patients with chronic HBV infection is 100 times greater than in healthy controls. Our previous studies showed that mutations in HBV genome mutations upregulate Skp2 expression, leading to increased risk of HCC. In this study, we demonstrated that Skp2 depletion resulted in KIF4A downregulation, and their expression correlated with each other in our HCC samples. Considering our HCC patients have a nearly 90% rate of HBV infection, we wondered if HBV infection would regulate KIF4A expression in HCC. In fact, a recent study reported that HBV activated the KIF4A gene promoter and upregulated the mRNA and protein expression levels of KIF4A in HCC cell lines. However, further investigations are needed to clarify the underlying mechanism of how HBV regulates KIF4A expression.

Our findings are meaningful for the following reasons. First, the scale of HCC samples is large, which could...
better demonstrate the result that KIF4A overexpression is associated with poor prognosis in HCC. Second, many studies have assessed clinicopathological factors based on 3-years survival, whereas we demonstrated that KIF4A exerted an additive effect over a longer period with the 8-years survival of patients with HCC. Third, it is the first time to demonstrate that knockdown of KIF4A could induce G2/M arrest and promote apoptosis in HCC cells. Fourth, we proposed that HBV may be involved in KIF4A regulation through a Skp2-mediated mechanism. However, our study also has limitations in that animal experiments are needed to validate KIF4A’s function in vivo and further investigations are awaited to explain the exact molecular mechanism behind association of Skp2 and KIF4A expression.

In conclusion, we demonstrated that KIF4A is over-expressed in HCC tissues and cell lines. Higher level of KIF4A in HCC patients predicts a poor prognosis. KIF4A depletion impairs cellular proliferation and colony formation abilities in HCC cells. Additionally, KIF4A expression is required for the maintenance of normal mitotic progression and protection from apoptosis in HCC cells. Taken together, KIF4A may act as a prognostic biomarker and potential therapeutic target in human HCC.

Materials and methods

Materials

The commercially available antibodies used are as follows: KIF4A (sc-365145, Santa Cruz), cleaved-caspase-3 (#9915, Cell Signaling Technology), cleaved-caspase-7 (#8438, Cell Signaling Technology), cleaved-poly ADP-ribose polymerase (PARP, #5625, Cell Signaling Technology), Bcl-2 (#4223, Cell Signaling Technology), Bax (#5023, Cell Signaling Technology), Akt (pan) (#4691, Cell Signaling Technology), p-Akt (ser473) (#4060, Cell Signaling Technology), p-Akt (Thr308) (#13038, Cell Signaling Technology) and Skp2 (#2652s, Cell Signaling Technology), CDC20 (10252-1-AP, Proteintech), cyclin B1 (#4138, Cell Signaling Technology), α-Tubulin (66031-1-lg, Proteintech), GAPDH (60004-1-lg, Proteintech) and Ki67 (MA5-14520, Rochford).

Patient selection and tissue preparation

We obtained the paraffin-embedded HCC specimens (n = 136) for prognostic survival analysis from Sun Yat-sen University Cancer Center (Guangzhou, China). For analysing the association between KIF4A and Ki67, another 53 fresh HCC specimens were collected from the Third Affiliated Hospital of Sun Yat-sen University (Guangzhou, China). A surgical tumour resection was performed on each patient in the Department of Hepatobiliary Surgery. Then tissues were cut into proper size and stored in liquid nitrogen directly for RNA and protein extraction or fixed in 4% paraformaldehyde for IHC. The study was approved by the Institute Research Ethics Committee at the Sun Yat-sen University Cancer Center and the Third Affiliated Hospital of Sun Yat-sen University (Guangzhou, China). Written informed consent was obtained from each patient. Relative experiments with these samples were performed in accordance with the relevant regulations.

Immunohistochemistry

IHC was performed as previously described. Briefly, all paraffin-embedded HCC samples were cut into 4-μm sections on a glass slide. Then these slides were dried overnight at 37 °C, deparaffinized in xylene twice for 10 min and rehydrated through graded alcohol five times for 5 min, immersed in 3% hydrogen peroxide for 15 min to block endogenous peroxidase. The sections were boiled in an electric pressure cooker in ethylenediamine tetraacetic acid (EDTA) buffer (pH = 8.0) to retrieve antigen for 3 min. Then, the slides were incubated with 10% normal goat serum at room temperature for 30 min to reduce nonspecific reaction. Sections were then incubated overnight with primary antibody against KIF4A, Ki67, or Skp2 at 4 °C and anti-rabbit/mouse secondary antibody at room temperature for 1 h. Signals were detected in a freshly prepared DAB substrate solution at room temperature for 5 min. Finally, the sections were counterstained with Mayer’s haematoxylin, dehydrated, and mounted. Each section was evaluated by three independent pathologists who were blinded to the clinical status of patients and graded as described, according to positive staining intensity (0 = no staining, 1 = weak staining, 2 = moderate staining, 3 = strong staining) and the expression extent scores (percentage of positive cells). A final immunoreactivity score (IRS) was defined as the intensity score multiplied by the extent score.

Cell culture

Eleven HCC cell lines (QGY-7703, BEL-7404, Hepa3B, MHCC-97L, Huh7, HepG2, PLC/PRC/5, BEL-7405, HepaG2.2.15, SMMC-7721 and SK-HEP-1) and two immortalized liver cells (THLE-2 and LO2) were employed in this study, cultured in Dulbecco’s Modification of Eagle’s Medium (DMEM, Gibco, Carlsbad, CA, USA) containing 10% foetal bovine serum (FBS, Gibco) at 37 °C and 5% CO2. THLE-2 was purchased from American Type Culture Collection (Manassas, VA, USA). Others were obtained from the College of Life Science, Sun Yat-sen University (Guangzhou, China). Cells were digested and passaged regularly.

Reverse transcription and quantitative PCR

Total RNA was isolated from tissue specimens and HCC cell lines using Trizol reagent (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s protocol. Total RNA (1 μg) was reverse transcribed into cDNA by the GoScript™ Reverse Transcription System (Promega). Quantitative PCR (qPCR) was performed in three duplicate wells by employing SYBR Green (Promega, USA) in Roche LightCycler 96 (Roche Applied Science, Penzberg, Germany). Specific primers were 5’-TACTGCGGTGGAGCAAGAGAAG-3’ (forward) and 5’-CATCTGCGCTTTGACGGAGAG-3’ (reverse) for KIF4A, and 5’-GGACGCGAGATCCCTCCAAAAT-3’ (forward) and 5’-GCTGTTGTCATACTTCTCATGG-3’ (reverse) for GAPDH.

Western blotting

Western blot assay was performed as standard procedure. Total protein was extracted using Radio Immunoprecipitation assay (RIPA) buffer with protease/ phosphatase inhibitor cocktail (Roche). Protein concentration was measured by BCA protein assay. Protein was then separated using 8–12% gradient polyacrylamide gel and then transferred onto polyvinylidene difluoride (PVDF) membranes. The membranes were blocked in Tris-buffered saline (TBS) containing 5% bovine serum albumin (BSA) at room temperature for 1 h and subsequently incubated with the indicated primary antibody at 4 °C overnight and then with the secondary antibody at room temperature for 1 h. Bands were visualized using the enhanced chemiluminescence (ECL, Pierce). Quantification of band densitometry was measured with ImageJ software.

Plasmid construction and RNA interference

KIF4A coding sequence was amplified and inserted into LV003-IRE5-EGFP (Forevergen Biosciences Co., Ltd). Lentiviruses were produced by co-transfecting constructed plasmids and packaging plasmids psPAX2 and pMD2.G (Addgene) into 293T using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) for about 72 h. Culture supernatants were collected, concentrated and filtered, concentrated and dialyzed, and then transferred onto polyvinylidene difluoride (PVDF) membranes. The targeted cells were blocked in Tris-buffered saline (TBS) containing 5% bovine serum albumin (BSA) at room temperature for 1 h and subsequently incubated with the indicated primary antibody at 4 °C overnight and then with the secondary antibody at room temperature for 1 h. Bands were visualized using the enhanced chemiluminescence (ECL, Pierce). Quantification of band densitometry was measured with ImageJ software.

Plasmid construction and RNA interference

KIF4A coding sequence was amplified and inserted into LV003-IRE5-EGFP (Forevergen Biosciences Co., Ltd). Lentiviruses were produced by co-transfecting constructed plasmids and packaging plasmids psPAX2 and pMD2.G (Addgene) into 293T using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) for about 72 h. Culture supernatants were collected, filtered, concentrated and used to infect SMMC-7721 and BEL-7404. After 48 h of infection, infected cells were selected by 2 μg/mL puromycin (540411, Merck) and successful establishment was confirmed by western blotting.

Two targeting KIF4A siRNA duplexes (KIF4A RNA#1, 5’-GGAAAGGGCAACAACCTCCT-3’; KIF4A RNA#2, 5’-TGAGGTGTTGATGGTGAT-3’) were obtained from Ribobio company (Guangzhou, China) and gave consistent results. Two targeting Skp2 siRNA duplexes were referenced on a published study. SMMC-7721 and BEL-7404 were transfected with 100 nM siRNA using Lipofectamine RNAiMAX according to the manufacturer’s protocol (Invitrogen, Carlsbad, CA, USA). Seventy-two hours later the RNA interference was confirmed using western blotting.

MTT cell viability assay

Cell proliferation rate was determined using MTT assay (M6494, Thermo) according to the manufacturer’s protocol. Cells were seeded in five replicates in a 96-well plate at a density of 2000 cells per well and cultured with DMEM containing 10% FBS. For 7 days, cells were incubated with 20 μL of 5 mg/mL MTT for 4 h at 37 °C. Subsequently, 150 μL of 100% dimethylsulphoxide (DMSO) was added to dissolve the precipitates. Viable cells were counted every day by reading the absorbance at 490 nm with a plate reader (BIOTEC800, BiTek).

Colonies formation assay

Thousand SMMC-7721 cells per well were plated in six-well plates and cultured in 37 °C for 14 days in DMEM with 10% FBS. In total 1500 BEL-7404 cells per well were seeded in six-well plates for 12 days. An additional culture medium was added to the plates on day 3. Cells were fixed with methanol, stained with 0.5% crystal violet (C6158, Sigma) and dried. The colony is defined to consist of at least 50 cells according to a previously described method, and all the colonies were counted using a microscope. The test was repeated three times.

Flow cytometry

For cell cycle analysis, cells were first synchronized at G1/S transition using double thymidine block as previously described, and harvested at 16 h after release in fresh medium. Then samples were washed twice in PBS, and then fixed in ice-cold 70% ethanol at −20 °C overnight. Fixed cells were treated with RNase A (R4875, Sigma-Aldrich) for 30 min at room temperature before addition of 5 μL/mL propidium iodide (PI, P4864, Sigma-Aldrich) for 10 min in the dark and analysed by flow cytometry.

For apoptosis analysis, cells were stained with annexin V-PE and 7-AAD (API04, Multi Sciences) and evaluated by flow cytometry according to the manufacturer’s protocol. Briefly, 1 × 10⁶ cells were washed twice with PBS and stained with 5 μL annexin V-PE and 10 μL 7-AAD in 1 × binding buffer for 15 min at room temperature in the dark. Apoptotic cells were determined using a Beckman-Coulter Flow Cytometry FC500. Both early (annexin V-positive/7-AAD-negative) and late (annexin V-positive/7-AAD-positive) apoptotic cells were included when assessing cell death.

Immunofluorescence analysis

Cells were plated on chamber slides, fixed with 4% paraformaldehyde at 37 °C for 5 min. To keep the stability of microtubule capture at kinetochores, cells were incubated for 5 min on ice before fixation, to destabilize most non-kinetochore microtubules. After fixation, cells were permeabilized with 0.1% triton for 5 min. Then cells were
were collected. The fluorescence-visualized secondary antibody was added and incubated for 60 min. Nucleus was stained with 50 ng/ml DAPI (4’,6-diamidino-2-phenylindole, D21490, Invitrogen) for 5 min at room temperature. Fluorescence signal was imaged using confocal microscope (LSM710, Zeiss). Multinucleated cells were defined as cells that have two or more nucleus per cell. The proportion of chromosome alignment errors was calculated as the ratio of multinucleated to total cells. At least 500 cells were counted for each group.

Oncomine data analysis
Oncomine (http://www.oncomine.com) is an integrated cancer microarray database that contains unified bioinformatics resources from 715 datasets (version 4.4.4.3 after Q2 update 2013)\(^1\). We compared the mRNA expression of KIF4A from liver cancer datasets that contain data from both HCC tissues and normal liver tissues. Four datasets were included in our study: Wurmbach et al.\(^2\), Roessler et al (including Roessler Liver datasets)\(^3\), and Mas et al.\(^4\). The differentiated expression for KIF4A between HCC tissues and normal liver tissues was analysed by t-test and their fold-change values and statistical significance determined by P-value were collected.

Statistical analysis
A paired t-test was used to analyse the different mRNA levels of KIF4A in HCC tissues and matched adjacent tissues. Independent t-test was applied to analyse differences between two groups. A chi-squared test was employed to analyse the relationship between KIF4A expression and clinicopathological characteristics. The Kaplan–Meier analysis was employed for the survival analysis. The Spearman’s correlation coefficient was employed for KIF4A and Skp2 correlation analysis. All of the statistical tests were performed using SPSS 20.0 statistical software (SPSS Company, Chicago, IL, USA).

Acknowledgements
This study was supported in part by grants from the National Natural Science Foundation of China (81371866), International Cooperation Project of Guangzhou Science and Technology Program (201704020175), the National Grant Program on Key Infectious Disease (2014ZX10002002), the National Natural Science Foundation Program on Key Infectious Disease (2014ZX10002002-002), Major Project of collaborative innovation of the Guangzhou Science and Technology Program (2016201604030021), the National Project Program on Key Infectious Disease (2014ZX10002002-002), Major Project of collaborative innovation of the Guangzhou Science and Technology Program (201704020175).

Author details
1Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. 2Guangdong Province Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. 3Department of Hepatobiliary Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

Author Contributions
Yanlin H., H. W., and Y. L. contributed equally to this work. Yanlin H. designed and performed experiments and generated figures. H. W. designed and performed experiments and analysed the data. Y. L. designed and performed experiments and drafted the manuscript. X. W. performed experiments. L. Z. performed experiments. J. W. performed experiments. M. D. collected samples and patients’ information, and obtained ethics approval. Yuehua H. advised on study design, supervised the experiments and data analysis, performed critical review of the manuscript and provided funding.

Conflict of interest
The authors declare that they have no conflict of interest.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information
The online version of this article (https://doi.org/10.1038/s41419-017-0114-4) contains supplementary material.

Received: 13 June 2017 Revised: 21 September 2017 Accepted: 30 October 2017
Published online: 02 February 2018

References
1. Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359–E386 (2015).
2. Forner, A., Gilabert, M., Bruix, J. & Raoul, J. L. Treatment of intermediate-stage hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 11, 525–535 (2014).
3. Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Primers 2, 16018 (2016).
4. Davison, M. A. & Kouzarides, T. Cancer epigenetics from mechanism to therapy. Cell 150, 12–27 (2012).
5. Huang, Y., Tai, A. W., Tong, S. & Lok, A. S. HBV core promoter mutations promote cellular proliferation through E2F1-mediated upregulation of S-phase kinase-associated protein 2 transcription. J. Hepatol. 58, 1068–1073 (2013).
6. Huang, Y., Tong, S., Tai, A. W., Hussain, M. & Lok, A. S. Hepatitis B virus core promoter mutations contribute to hepatocarcinogenesis by deregulating SKP2 and its target, p21. Gastroenterology 141, 1412–1421 (2011).
7. Kops, G. J., Weaver, B. A. & Cleveland, D. W. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat. Rev. Cancer 5, 773–785 (2005).
8. Liu, X., Gong, H. & Huang, K. Oncogenic role of kinesin proteins and targeting kinesin therapy. Cancer Sci. 104, 651–656 (2013).
9. Lawrence, C. J. et al. A standardized kinesin nomenclature. J. Cell. Biol. 167, 19–22 (2004).
10. Miki, H., Setou, M., Kaneshiro, K. & Hirokawa, N. All kinesin superfamily proteins, IFK, genes in mouse and human. Proc. Natl Acad. Sci. USA 98, 7004–7011 (2001).
11. Wu, G. & Chen, P. L. Structural requirements of chromokinesin KIF4A for its proper function in mitosis. Biochem. Biophys. Res. Commun. 372, 454–458 (2008).
12. Tanikawa, M. et al. Activation of KIF4A as a prognostic biomarker and therapeutic target for lung cancer. Clin. Cancer Res. 13, 6624–6631 (2007).
13. Minakawa, Y. et al. Kinesin family member 4A: a potential predictor for progression of human oral cancer. PLoS ONE 8, e69591 (2013).
14. Narayan, G. et al. Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and overexpressed genes. Genes Chromosomes Cancer 46, 373–384 (2007).
15. Colek, D. et al. Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young women. PLoS ONE 8, e83284 (2013).
16. Zhou, J. X. et al. Kinesin family deregulation coordinated by bromodomain protein ANCCA and histone methyltransferase MLL for breast cancer cell growth, survival, and tamoxifen resistance. Mol. Cancer Res. 12, 539–549 (2014).
17. Rhodes, D. R. et al. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc. Natl Acad. Sci. USA 101, 9309–9314 (2004).

18. Schnerch, D. et al. Cell cycle control in acute myeloid leukemia. Am. J. Cancer Res. 2, 506–528 (2012).

19. Xu, Y. et al. KIF4 regulates the expression of VEGFR1 through the PI3K/Akt signaling pathway in RAW264.7 monocytes/macrophages. Int. J. Mol. Med. 39, 1285–1290 (2017).

20. Hao, Z. & Huang, S. E3 ubiquitin ligase Skp2 as a target for cancer therapy. Front. Biosci. 20, 474–490 (2015).

21. Calvisi, D. F. et al. SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis. Gastroenterology 137, 1816–1826 (2009). e1811-1810.

22. Xu, H. et al. Silencing of KIF14 interferes with cell cycle progression and cytokinesis by blocking the p27(Kip1) ubiquitination pathway in hepatocellular carcinoma. Exp. Mol. Med. 46, e97 (2014).

23. Yu, Y. & Feng, Y. M. The role of kinesin family proteins in tumorigenesis and progression: potential biomarkers and molecular targets for cancer therapy. Cancer 116, 5150–5160 (2010).

24. Mazumdar, M., Sundaresan, S. & Misteli, T. Human chromokinesin KIF4A functions in chromosome condensation and segregation. J. Cell Biol. 166, 613–620 (2004).

25. Cotter, T. G. Apoptosis and cancer: the genesis of a research field. Nat. Rev. Cancer 9, 501–507 (2009).

26. Stiles, B. L. PI-3-K and AKT: onto the mitochondria. Adv. Drug Deliv. Rev. 61, 1276–1282 (2009).

27. Huang, Y. & Lok, A. S. Viral factors and outcomes of chronic HBV infection. Am. J. Gastroenterol. 106, 93–95 (2011).

28. Chen, L. et al. HBV core promoter mutations and AKT upregulate S-phase kinase-associated protein 2 to promote postoperative hepatocellular carcinoma progression. Sci. Rep. 6, 35917 (2016).

29. Yang, H. I. et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J. Natl. Cancer Inst. 100, 1134–1143 (2008).

30. Geer, A., Gartung, C., Dietrich, C. G. & Hepatitis, B e Antigen and the risk of hepatocellular carcinoma. N. Engl. J. Med. 347,1721–1722 (2002).

31. Zhu, C. L. et al. Hepatitis B virus upregulates the expression of kinesin family member 4A. Mol. Med. Rep. 12, 3503–3507 (2015).

32. Liu, X. et al. Direct reprogramming of human fibroblasts into dopaminergic neuron-like cells. Cell. Res. 22, 321–332 (2012).

33. Jiang, F., Caraway, N. P., Li, R. & Katz, R. L. RNA silencing of S-phase kinase-interacting protein 2 inhibits proliferation and centrosome amplification in lung cancer cells. Oncogene 24, 3409–3418 (2005).

34. Franken, N. A., Rodermond, H. M., Stap, J., Haveman, J. & van Bree, C. Clonogenic assay of cells in vitro. Nat. Protoc. 1, 2315–2319 (2006).

35. Liu, X. et al. Antroquinonol displays anticancer potential against human hepatocellular carcinoma cells: a crucial role of AMPK and mTOR pathways. Biochem. Pharmacol. 79, 162–171 (2010).

36. Rhodes, D. R. et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6, 1–6 (2004).

37. Wurmbach, E. et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. J. Hepatol. 45, 938–947 (2007).

38. Roessler, S. et al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 70, 10202–10212 (2010).

39. Mas, V. R. et al. Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma. Mol. Med. 15, 85–94 (2009).